Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-07-24 pm EDT 5-day change 1st Jan Change
27.94 USD +0.11% Intraday chart for Perrigo Company plc +0.79% -13.18%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating MT
Perrigo Divests HRA Pharma Rare Diseases Business to Esteve Healthcare MT
Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc. CI
Piper Sandler Adjusts Price Target on Perrigo to $36 From $39, Maintains Overweight Rating MT
Transcript : Perrigo Company plc Presents at Oppenheimer's 24th Annual Virtual Consumer Growth and E-Commerce Conference, Jun-11-2024 01:30 PM
Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024 CI
Perrigo Company plc Announces Executive Changes CI
Tranche Update on Perrigo Company plc's Equity Buyback Plan announced on November 8, 2018. CI
Perrigo's Q1 Adjusted Earnings, Net Sales Drop MT
Transcript : Perrigo Company plc, Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 Revenue $1.08B MT
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q1 EPS $0.29, vs. Street Est of $0.23 MT
Perrigo Company plc Reports Earnings Results for the First Quarter Ended March 30, 2024 CI
Perrigo Company plc Reaffirms Earnings Guidance Year 2024 and Provides Sales Guidance for the Second Half of 2024 CI
Perrigo Announces Executive Transition for Its Consumer Self-Care International Business CI
Perrigo Keeps Quarterly Dividend at $0.276 Per Share; Payable June 18 to Shareholders on May 31 MT
Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024 CI
Sector Update: Health Care Stocks Decline Late Afternoon MT
Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million MT
Esteve Healthcare S.L. entered into a Purchase and Sale Agreement to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc for approximately ?280 million. CI
Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost MT
Multiple CVS Caremark Plans Reportedly to Cover Perrigo's Opill at No Cost MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Chart Perrigo Company plc
More charts
Logo Perrigo Company plc
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
Employees
9,140
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
27.94USD
Average target price
38.50USD
Spread / Average Target
+37.80%
Consensus
  1. Stock Market
  2. Equities
  3. PRGO Stock
  4. News Perrigo Company plc
  5. Piper Sandler Adjusts Price Target on Perrigo to $36 From $39, Maintains Overweight Rating